Latest News

Avidity Biosciences Announces Pricing of Initial Public Offering

SAN DIEGO, June 11, 2020 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq:RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its initial public offering of 14,400,000 shares of common stock at a public offering price of $18.00 per share. The shares are expected to begin trading on the […]

Avidity Biosciences Appoints Michael MacLean as Chief Financial Officer

SAN DIEGO, May 19, 2020 /PRNewswire/ — Avidity Biosciences (Avidity), a privately-held biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Michael MacLean as Chief Financial Officer. “Mike is a leader who has successfully built and led financial teams for several biotechnology companies during their critical phases of growth,” said Sarah Boyce, President […]

Avidity Biosciences Appoints Carsten Boess to its Board of Directors

SAN DIEGO, April 13, 2020 /PRNewswire/ – Avidity Biosciences (Avidity), a privately-held biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Carsten Boess to its board of directors.  Mr. Boess, who has nearly thirty years of industry experience as a finance executive and board member, brings a wealth of experience in financing, leading […]

Avidity Biosciences Announces Presentations at Upcoming Investor Conferences

SAN DIEGO, Feb. 24, 2020 /PRNewswire/ — Avidity Biosciences (Avidity), a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today that Sarah Boyce, Avidity’s President and CEO, will present a company overview at two upcoming investor conferences: 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 1:30 pm ET at the Lotte New […]

Avidity Biosciences Appoints Joseph Baroldi as Chief Operating Officer

SAN DIEGO, Feb. 12, 2020 /PRNewswire/ — Avidity Biosciences, Inc. (Avidity), a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Joseph Baroldi as Chief Operating Officer. “We are thrilled to welcome Joe to the Avidity team,” said Sarah Boyce, President and CEO of Avidity.  “His industry experience and depth of strategic expertise […]

Avidity Biosciences Completes $100 Million Series C Financing

La Jolla, Calif., November 13, 2019 (BUSINESS WIRE) – Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs™) for the treatment of rare muscle disorders and other serious diseases, announced the completion of a $100 million Series C financing. The financing was led by RTW Investments and included new investors Cormorant Asset Management, LP, CureDuchenne, […]

Avidity Biosciences Appoints Sarah Boyce as Chief Executive Officer

La Jolla, California, October 1, 2019 (PRNewswire) — Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of global business leader Sarah Boyce as President and Chief Executive Officer and a member of the Avidity Board of Directors. “We are delighted to welcome Sarah as the new CEO of […]

Avidity Biosciences to Present at the 2019 Myotonic Annual Conference

La Jolla, California, September 12, 2019 (PRNEWSWIRE) – Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), today announced that Arthur A. Levin, Ph.D., Chief Scientific Officer, is scheduled to present at the 2019 Myotonic Annual Conference on Saturday, September 14 at 4:00 p.m. ET. The conference will be held September 13-14, 2019 […]